Good price. TD Waterhouse and loan loss provisions have hurt. Could drop further, but good long term.

Demographics for pharmaceuticals is good. Could be volatile during their election period. Good long term.

Has a lot of problems. There could be more bad news.

Still vulnerable. Guidance is too high. Will take time.

Well run. Cyclical. Weakening of economy has made it vulnerable. Likes their Methanex holdings. Buy for long term.

Has done well. 30% of sales are in Europe which could make them vulnerable. Not a cheap stock.

Lagged because of their hedging strategy, but now cleaning these up. Sells at a discount to other golds, so could move up.